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Abstract
Background: Pulmonary alveolar proteinosis is a rare lung disorder, which was first reported as
idiopathic condition in 1958. The prevalence of acquired pulmonary alveolar proteinosis has been
estimated to be 0.37 per 100,000 population. The cause of this condition is not entirely clear. We
present alveolar proteinosis in a case recently treated for pulmonary Pneumocystis carinii infection.
Case presentation: A 25-year-old Caucasian female presented with shortness of breath during
management of acute pancreatitis. She had a heart-transplant six years ago, a distal pancreatectomy
secondary to pancreatitis two years ago, chronic renal failure secondary to Prograft taken for six
years to suppress transplant rejection, and a more recent history of Pneumocystis carinii infection
treated in the preceding 21 days with augmented doses of Bactrim (Trimethoprim,
Sulfamethoxazole). She had bilateral pleural effusions with radiological and clinical features
suspicious for interstitial lung disease. Cytopathologic evaluation of broncho-alveolar lavage (BAL)
showed hyaline alveolar casts admixed with amorphous debris and scant chronic inflammatory
cells, consistent with alveolar proteinosis. GMS and PAS stains were negative for P. carinii. Direct
Fluorescent Antibody (DFA) test for P. carinii performed on the BAL specimen in our Microbiology
Lab had been repeatedly negative.
Conclusion: Cytopathological findings in bronchoalveolar lavage, with clinical differential diagnosis
of interstitial lung disease, were diagnostic. Pulmonary alveolar proteinosis after recent treatment
for P. carinii infection suggests a relationship of pulmonary alveolar proteinosis with P. carinii
infection in the immunocompromised patient.
Background
Pulmonary alveolar proteinosis is an accumulation of
abundant extra cellular periodic acid-Schiff (PAS) positive
proteinaceous material in alveolar spaces. It was first
described as an idiopathic condition in 1958 [1]. This
material represents surfactant distending the alveolar
space. Papanicolaou-stained smears of bronchoalveolar
lavage (BAL) fluid show characteristic hyaline globular
alveolar casts which are green, or orange, or centrally
orange with a green rim [2]. The globules may show scant
cells "hugging" the periphery, which appear to be
imprints of the pulmonary alveoli with occasional carry-
over of pneumocytes lining the alveoli. Electron micros-
copy demonstrates whorled myelin figures characteristic
of surfactant [3].
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Case presentation
A 25-year-old Caucasian female with a history of heart
transplant, presented with shortness of breath. Twenty
one days prior to her presentation, she had P. carinii pneu-
monia for which she was treated with augmented doses of
Bactrim (Trimethoprim, Sulfamethoxazole). She also
noticed a progressive lower extremity edema, pleuritic
chest pain, dry cough, and chills. She was diagnosed as
chronic renal failure and was started on hemodialysis as
an outpatient. During hemodialysis, she experienced
abdominal pain radiating to the back. She presented to
the emergency room with acute respiratory distress syn-
drome and acute pancreatitis secondary to a stone in the
pancreatic duct. She was admitted and shortly after, she
required intubation because of decreased oxygen satura-
tion. A chest X-ray showed increased interstitial markings,
suggestive of interstitial lung disease. Bilateral pleural
effusions were also noted and attributed to the chronic
renal failure with fluid overload. Recurrence of P. carinii
infection was also considered a possibility. BAL was per-
formed as part of a diagnostic-treatment protocol and 15
cc of cloudy pinkish fluid was sent for cytopathologic
evaluation. Two Papanicolaou (PAP) stained SurePath™
preparations were prepared.
The PAP stained SurePath preparations showed character-
istic globular alveolar casts of amorphous material which
stained green, orange, and centrally orange with a green
rim (Figure 1). This material was PAS positive and was
resistant to diastase (Figure 2). GMS stain (Figure 3) did
not show the characteristic crushed ping-pong ball like
structures with central to eccentric dots (Figure 3a,b)
Characteristic globular alveolar casts of amorphous cyanophilic to acidophilic debris (a) are admixed with relatively scant cells  (b) Figure 1
Characteristic globular alveolar casts of amorphous cyanophilic to acidophilic debris (a) are admixed with relatively scant cells 
(b). Some hyaline globules demonstrate two tone staining (c). The globules of variable sizes range in shapes and dimensions 
corresponding with alveolar spaces. Occasional pneumocytes may be seen "hugging" the periphery of globules (arrow in d). 
This is different from the frothy appearance of casts associated with P. carinii pneumonia which show individual vacuoles with 
central to eccentric dots. (Bronchoalveolar lavage; Papanicolaou stained SurePath Prep™).
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observed in the frothy casts associated with P. carinii
pneumonia (Figure 3c,d).
Oxygen saturation improved after BAL procedure. Three
days later she was extubated, and was discharged within a
week. Apart from a hysterectomy for severe cervical dys-
plasia six months after this event, she has had an unevent-
ful healthy course. Currently she is alive and well.
Discussion
Although pulmonary alveolar proteinosis is usually diffi-
cult to differentiate clinically and radiologically from
interstitial lung disease, it can be recognized in BAL. BAL
fluid in alveolar proteinosis is usually opaque on gross
appearance. Proper interpretation of BAL in these cases
spares the patient an open lung biopsy. This is especially
important for debilitated or transplant patients, because
pulmonary alveolar proteinosis may be amenable to treat-
ment by a simple procedure such as BAL alone.
The globular alveolar casts of pulmonary alveolar protei-
nosis should be distinguished from foamy alveolar casts
of P. carinii in BAL specimens. In alveolar proteinosis the
globular structures are hyaline as compared to foamy in P.
carinii. The globular extra cellular hyaline material is PAS
(diastase resistant) positive (Figure 2). The morphological
details should be scrutinized under higher magnification,
especially at the periphery of these casts. The foamy casts
in P. carinii show distinct dark dots in individual vacuoles
even in PAP stained preparations. If the details cannot be
appreciated in PAP stained preparations, special stain
such as GMS are helpful (Figure 3). P. carinii organisms
demonstrate characteristic crushed "ping-pong" ball-like
GMS stained dark P. carinii cysts-structures in the frothy
casts (Figure 3c,d). They are not present in the hyaline
casts of alveolar proteinosis (Figure 3a,b). For further
comparison of P. carinii and PAP, see Table-1.
As demonstrated in humans and mouse models,
ultrastructurally the alveolar spaces in pulmonary alveolar
proteinosis show numerous lamellar bodies with a struc-
tural resemblance to myelin. These lamellar bodies are
similar to the surfactant present in type II pneumocytes. It
is hypothesized that hyperplasic and hypertrophic type II
pneumocytes produce increased amounts of lamellar
bodies and develop into mononucleated giant balloon
cells [4]. When they rupture, these mononucleated giant
cells liberate numerous myelinoid structures, lipid drop-
lets, and many electron dense amorphous acicular crystals
which are closely associated with the extracellular mem-
branous material.
Pulmonary alveolar proteinosis occurs in three clinically
distinct forms: idiopathic, congenital, and secondary [5].
Idiopathic  pulmonary alveolar proteinosis has been an
enigmatic acquired disorder since its initial description
[1]. The exact etiology of this variant is not entirely clear
but appears to be multifactorial, comprising the com-
bined effect of infectious, environmental and hereditary
factors.
The congenital form comprises of a heterogeneous group
of disorders [6] caused by mutations in the genes encod-
The extra-cellular globular hyaline material is homogeneously PAS positive after diastase (a, b) without any organisms, as com- pared to the presence of organisms in P. carinii associated frothy alveolar casts (see figure 3) Figure 2
The extra-cellular globular hyaline material is homogeneously PAS positive after diastase (a, b) without any organisms, as com-
pared to the presence of organisms in P. carinii associated frothy alveolar casts (see figure 3). (Bronchoalveolar lavage; Periodic-
Acid Schiff (PAS) stained SurePath Prep™)
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ing surfactant protein B or C or the βC chain of the receptor
for granulocyte-macrophage colony-stimulating factor
(GM-CSF) [7-11].
Most of the studies report the congenital form of alveolar
proteinosis. One possible explanation for this form
revolves around surfactant. Normally, surfactant is inacti-
vated by mechanical and biologic processes and converted
into small, surface-inactive aggregates. Approximately 70
to 80 percent of the small aggregates are taken up by alve-
olar type II pneumocytes, transported to phagolysosomes,
and reused or catabolized. Alveolar macrophages internal-
ize and catabolize the remaining surfactant pool, a proc-
ess critically dependent on GM-CSF. Some patients with
alveolar proteinosis have shown to have genetic defects
rendering the GM-CSF receptor ineffective. The interrup-
Table 1: 
Characteristic Features Pulmonary Alveolar Proteinosis Pneumocystis Carinii
Appearance of the alveolar cast-like structures Hyaline Foamy
Crushed "ping-pong" ball-like cyst-structures Absent Present
Dark central dots in the cyst-like structures by fungal stains (GMS, PAS) Absent Present
Back-ground debris Could be present Absent
The hyaline globules in the amorphous material do not show any organisms with GMS stain (a, b) Figure 3
The hyaline globules in the amorphous material do not show any organisms with GMS stain (a, b). Compare this with appear-
ance of PCP in positive control (c, d), which shows frothy casts with the characteristic crushed ping-pong ball like organisms (c) 
with small central to eccentric dots (arrow in d). (Bronchoalveolar lavage; Gomori-Silver Methanamine (GMS) stained SurePath 
Prep™).
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tion of GM-CSF signaling in the alveolar macrophage, for
example, by targeted ablation of the gene encoding GM-
CSF or its receptor in mice or, presumably, by neutralizing
anti-GM-CSF auto antibodies in humans, causes accumu-
lations of eosinophilic lipoproteinaceous material and
large, foamy macrophages in the alveoli [12].
The secondary pulmonary alveolar proteinosis develops in
association with conditions involving functional impair-
ment or reduced numbers of alveolar macrophages. Such
conditions include some hematologic malignancies,
pharmacologic immune suppression, inhalation of inor-
ganic dust (e.g., silica) or toxic fumes, and certain infec-
tions [13].
The relationship of pulmonary alveolar proteinosis with
recently treated P. carinii infection has not been specifi-
cally stressed previously. However, one case from a series
describing spectrum of morphological changes in alveolar
spaces, associates co-trimoxazole (Trimethoprim, Sulfam-
ethoxazole) treated P. carinii pneumonia with alveolar
proteinosis. Ultra structural examination of alveoli in case
number 5 of this study showed lamellar-body-like struc-
tures resembling those of alveolar proteinosis [14]. Our
case was also recently treated for P. carinii infection with
Bactrim (Trimethoprim, Sulfamethoxazole, co-trimoxa-
zole). The patient improved after BAL and was discharged.
This case suggests a link between treated P. carinii infec-
tion and pulmonary alveolar proteinosis in this immuno-
compromised heart transplant patient. The treated P.
carinii organisms may lead to accumulation of lamellar-
body-like structures in alveolar spaces with resultant alve-
olar proteinosis, which if diagnosed correctly could be
treated with appropriate therapy including relatively sim-
ple procedure such as BAL. Similar reports have linked
pulmonary alveolar proteinosis with Mycobacterium
avium-intracellulare  [15] and also with active P. carinii
infection as well as other opportunistic infections [16].
The later report also stresses the connection between
immunosuppressed patients and pulmonary alveolar pro-
teinosis.
In summary, this case highlights the importance of differ-
entiating  P. carinii infection from alveolar proteinosis
with emphasis on correct differentiation of the frothy
globular casts in P. carinii infection from the hyaline glob-
ular casts in alveolar proteinosis. Correct interpretation of
BAL would facilitate proper management and clinical
recovery. A relationship between Bactrim treated PCP and
Pulmonary Alveolar Proteinosis should be considered
during the management of such cases.
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